Aura Biosciences, Inc Rings the Closing Bell

ABOUT THIS EVENT

Aura Biosciences, Inc (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, visits the Nasdaq MarketSite in Times Square.

In honor of the occasion, Elisabet de los Pino, CEO, rings the Closing Bell.

Nasdaq Originals Exclusive insights on the forces shaping the convergence of technology, business and sports. Explore